NERVGEN PHARMA CORP (NGEN) Institutional Ownership Changes & 13F Activity
NERVGEN PHARMA CORP (NGEN). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q2 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Empery Asset Management, Lp, Rock Springs Capital Management Lp, Dafna Capital Management Llc, Ghisallo Capital Management Llc, and Armistice Capital, Llc.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| Integrated Wealth Concepts Llc | Sell | -12,600 | -14.5% | 74,215 | $152.88K | Q2 2026 | Sep 09, 2026 |
| Stonepine Capital Management, Llc | Buy | +271,678 | — | 271,678 | $559.66K | Q2 2026 | Aug 17, 2026 |
| Rock Springs Capital Management Lp | Buy | +1,208,231 | — | 1,208,231 | $2.49M | Q2 2026 | Aug 14, 2026 |
| Dafna Capital Management Llc | Buy | +1,050,000 | — | 1,050,000 | $2.16M | Q2 2026 | Aug 14, 2026 |
| Ghisallo Capital Management Llc | Buy | +1,000,000 | — | 1,000,000 | $2.06M | Q2 2026 | Aug 14, 2026 |
| Armistice Capital, Llc | Buy | +678,000 | — | 678,000 | $1.40M | Q2 2026 | Aug 14, 2026 |
| Lmr Partners Llp | Buy | +600,000 | — | 600,000 | $1.24M | Q2 2026 | Aug 14, 2026 |
| Jane Street Group, Llc | Buy | +270,750 | — | 270,750 | $557.75K | Q2 2026 | Aug 14, 2026 |
| Woodline Partners Lp | Buy | +250,500 | — | 250,500 | $516.03K | Q2 2026 | Aug 14, 2026 |
| Millennium Management Llc | Buy | +39,740 | — | 39,740 | $81.86K | Q2 2026 | Aug 14, 2026 |
| Hrt Financial Lp | Buy | +22,492 | +105.3% | 43,858 | $90.00K | Q2 2026 | Aug 14, 2026 |
| Wells Fargo & Company/Mn | Buy | +22,000 | — | 22,000 | $45.32K | Q2 2026 | Aug 14, 2026 |
| Goldman Sachs Group Inc | Buy | +19,623 | — | 19,623 | $40.42K | Q2 2026 | Aug 14, 2026 |
| Bank Of America Corp | Sell | -14,456 | -7.2% | 186,200 | $383.57K | Q2 2026 | Aug 14, 2026 |
| Osaic Holdings, Inc. | Buy | +11,102 | +27.8% | 51,093 | $105.25K | Q2 2026 | Aug 14, 2026 |
| Royal Bank Of Canada | Buy | +4,114 | +2.4% | 176,075 | $363.00K | Q2 2026 | Aug 14, 2026 |
| Jones Financial Companies Lllp | Buy | +2,774 | +277.4% | 3,774 | $7.06K | Q2 2026 | Aug 14, 2026 |
| Federation Des Caisses Desjardins Du Quebec | Buy | +2,500 | — | 2,500 | $5.15K | Q2 2026 | Aug 14, 2026 |
| Ubs Group Ag | Buy | +318,209 | +517.3% | 379,726 | $782.24K | Q2 2026 | Aug 13, 2026 |
| Marshall Wace, Llp | Buy | +235,603 | +117.6% | 435,962 | $898.08K | Q2 2026 | Aug 13, 2026 |
| Virtu Financial Llc | Buy | +34,589 | — | 34,589 | $71.00K | Q2 2026 | Aug 13, 2026 |
| Captrust Financial Advisors | Buy | +2,056 | +3.3% | 64,423 | $132.71K | Q2 2026 | Aug 13, 2026 |
| Steward Partners Investment Advisory, Llc | Buy | +1,897 | +46.2% | 6,000 | $12.36K | Q2 2026 | Aug 13, 2026 |
| Morgan Stanley | Buy | +957 | +8.0% | 12,939 | $26.65K | Q2 2026 | Aug 13, 2026 |
| Cibc World Market Inc. | Buy | +400 | +3.8% | 10,960 | $22.58K | Q2 2026 | Aug 13, 2026 |
| Geode Capital Management, Llc | Buy | +58,040 | — | 58,040 | $119.56K | Q2 2026 | Aug 12, 2026 |
| Bank Of Montreal | Buy | +15,494 | +24.6% | 78,394 | $284.38K | Q2 2026 | Aug 12, 2026 |
| Jpmorgan Chase & Co | Buy | +14,714 | — | 14,714 | $28.84K | Q2 2026 | Aug 12, 2026 |
| Empery Asset Management, Lp | Buy | +4,000,000 | — | 4,000,000 | $8.24M | Q2 2026 | Aug 11, 2026 |
| Scotia Capital Inc. | Sell | -258 | -2.0% | 12,740 | $26.34K | Q2 2026 | Aug 11, 2026 |
Frequently asked questions about NGEN activity
Which institutional owners are buying NGEN?
Institutional owners buying NGEN include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in NGEN activity?
"Buy" means an investor increased their reported position in NGEN compared to the prior reporting period. This reflects growing exposure to NERVGEN PHARMA CORP (NGEN) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in NGEN increasing?
Institutional interest in NGEN can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.